CN100392087C - 黄病毒疫苗输送系统 - Google Patents

黄病毒疫苗输送系统 Download PDF

Info

Publication number
CN100392087C
CN100392087C CNB028275624A CN02827562A CN100392087C CN 100392087 C CN100392087 C CN 100392087C CN B028275624 A CNB028275624 A CN B028275624A CN 02827562 A CN02827562 A CN 02827562A CN 100392087 C CN100392087 C CN 100392087C
Authority
CN
China
Prior art keywords
replicon
rna
protein
virus
flavivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028275624A
Other languages
English (en)
Chinese (zh)
Other versions
CN1671851A (zh
Inventor
亚历山大·A.·赫罗梅赫
安德烈亚斯·祖尔比尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO TECH Co Ltd
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR9093A external-priority patent/AUPR909301A0/en
Priority claimed from AU2002950974A external-priority patent/AU2002950974A0/en
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Publication of CN1671851A publication Critical patent/CN1671851A/zh
Application granted granted Critical
Publication of CN100392087C publication Critical patent/CN100392087C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB028275624A 2001-11-26 2002-11-26 黄病毒疫苗输送系统 Expired - Fee Related CN100392087C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR9093A AUPR909301A0 (en) 2001-11-26 2001-11-26 Flavivirus vaccine system
AUPR9093 2001-11-26
AU2002950974 2002-07-29
AU2002950974A AU2002950974A0 (en) 2002-07-29 2002-07-29 Flavivirus vaccine system

Publications (2)

Publication Number Publication Date
CN1671851A CN1671851A (zh) 2005-09-21
CN100392087C true CN100392087C (zh) 2008-06-04

Family

ID=25646850

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028275624A Expired - Fee Related CN100392087C (zh) 2001-11-26 2002-11-26 黄病毒疫苗输送系统

Country Status (7)

Country Link
US (1) US20060204523A1 (enExample)
EP (1) EP1461441A4 (enExample)
JP (1) JP2005510244A (enExample)
CN (1) CN100392087C (enExample)
CA (1) CA2467397A1 (enExample)
NZ (1) NZ533237A (enExample)
WO (1) WO2003046189A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454022B (zh) * 2006-02-27 2013-09-04 得克萨斯系统大学评议会 假性感染性黄病毒及其用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1593738A4 (en) * 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
AU2004245578B2 (en) * 2003-06-06 2008-10-30 Replikun Biotech Pty Ltd Flavivirus replicon packaging system
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
US20070036827A1 (en) * 2003-10-29 2007-02-15 The University Of Queensland West nile virus vaccine
US8815564B2 (en) 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
ES2649896T3 (es) * 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
SI2714071T1 (sl) * 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
WO2015118146A1 (en) 2014-02-10 2015-08-13 Univercells Nv System, apparatus and method for biomolecules production
CA2999916C (en) * 2015-09-23 2021-07-20 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
CN110381993B (zh) * 2017-02-14 2024-03-29 得克萨斯大学体系董事会 具有3’utr缺失的活减毒寨卡病毒、含有所述病毒的疫苗及其用途
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2021108863A1 (en) * 2019-12-03 2021-06-10 The Council Of The Queensland Institute Of Medical Research Defective interfering particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028487A1 (en) * 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines
CN1253506A (zh) * 1997-02-28 2000-05-17 奥拉瓦克斯公司 嵌合黄病毒疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
JP5480458B2 (ja) * 1999-08-09 2014-04-23 サンド・アクチエンゲゼルシヤフト 自己タンパク質分解切断によるタンパク質の製造
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
WO2001060847A2 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1253506A (zh) * 1997-02-28 2000-05-17 奥拉瓦克斯公司 嵌合黄病毒疫苗
WO1999028487A1 (en) * 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Recombinant yellow fever viruses are effective therapcuticvaccines for treatment of murine experimental solid tumorsand pulmonary meatastases.. McAllister等.J.Virology. 2000 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454022B (zh) * 2006-02-27 2013-09-04 得克萨斯系统大学评议会 假性感染性黄病毒及其用途

Also Published As

Publication number Publication date
CA2467397A1 (en) 2003-06-05
HK1081987A1 (zh) 2006-05-26
WO2003046189A1 (en) 2003-06-05
NZ533237A (en) 2005-11-25
EP1461441A4 (en) 2006-02-22
EP1461441A1 (en) 2004-09-29
CN1671851A (zh) 2005-09-21
JP2005510244A (ja) 2005-04-21
US20060204523A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
CN100392087C (zh) 黄病毒疫苗输送系统
Anraku et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity
KR101518309B1 (ko) 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US10570416B2 (en) TC-83-derived alphavirus vectors, particles and methods
US8048427B2 (en) Subgenomic replicons of the flavivirus dengue
JP7240029B2 (ja) フラビウイルスとリッサウイルスとのキメラワクチン
NZ543419A (en) Flavivirus replicon packaging system
JP2019535291A (ja) プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン
Anraku et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines
AU2002342415B2 (en) Flavivirus vaccine delivery system
HK1081987B (en) Flavivirus vaccine delivery system
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
Davis et al. RNA virus replicon vaccines
US20220402976A1 (en) Chimeric filovirus vaccines
US20200316187A1 (en) Chimeric yellow fever zika virus strain
Makia Development of a novel dendritic cell targeting vaccine platform based on mouse hepatitis coronavirus multigene RNA vectors
AU2004245578A1 (en) Flavivirus replicon packaging system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081987

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: LEIPRIQUEEN BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: UNIV QUEENSLAND; QUEENSLAND INSTITUTE OF MEDICAL RESEARCH COUNCIL

Effective date: 20080718

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080718

Address after: Queensland, Australia

Patentee after: Bio Tech Co., Ltd.

Address before: Queensland, Australia

Co-patentee before: The Council of the Queensland Inst. of Medical Research

Patentee before: University of Queensland

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1081987

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080604

Termination date: 20091228